Combination of agomelatine and bupropion for treatment-resistant depression: results from a chart review study including a matched control group

Introduction: Although a growing selection of antidepressants is available, a significant number of patients do not reach clinical remission, despite multiple trials. Data concerning the efficacy and safety of combination therapies with newer antidepressants are limited. Methods: Fifteen inpatients with treatment-resistant depression (TRD), defined as Beck Depression Inventory-2 (BDI-2) scores \u3e14 despite treatment with adequate doses of 1 antidepressant classes for 6weeks, were treated with agomelatine plus bupropion for 6weeks, and compared to 15 patients on antidepressant monotherapy with TRD matched on age, sex, and TRD stage based on retrospective chart review. The primary outcome was change in BDI-2 scores. Secondary outcomes included treatment response (BDI-2 score decrease by 50%), remission (BDI-2 scor